Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
CNY 1.69
(0.0%)
CNY 1.69
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.51 Billion CNY | -56.06% |
| 2022 | 5.44 Billion CNY | 28.19% |
| 2021 | 4.3 Billion CNY | 485.47% |
| 2020 | 743.69 Million CNY | -43.44% |
| 2019 | 1.27 Billion CNY | 6.72% |
| 2018 | 1.04 Billion CNY | 0.33% |
| 2017 | 1.17 Billion CNY | 41.26% |
| 2016 | 859.08 Million CNY | 14.21% |
| 2015 | 690.68 Million CNY | -35.39% |
| 2014 | 1.05 Billion CNY | 225.05% |
| 2013 | 350.1 Million CNY | -49.48% |
| 2012 | 677.28 Million CNY | -13.29% |
| 2011 | 801.39 Million CNY | 82.98% |
| 2010 | 424.9 Million CNY | 205.25% |
| 2009 | 145.18 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 74.45 Million CNY | -46.83% |
| 2024 Q3 | 37.98 Million CNY | -91.93% |
| 2024 Q2 | 453.16 Million CNY | 52.76% |
| 2023 Q3 | 476.71 Million CNY | 61.04% |
| 2023 Q4 | 530.65 Million CNY | 11.31% |
| 2023 FY | - CNY | -56.06% |
| 2023 Q1 | 499.89 Million CNY | -3.57% |
| 2023 Q2 | 296.03 Million CNY | -40.78% |
| 2022 Q2 | 1.89 Billion CNY | 50.33% |
| 2022 FY | - CNY | 28.19% |
| 2022 Q4 | 518.42 Million CNY | -42.84% |
| 2022 Q1 | 1.26 Billion CNY | 5.18% |
| 2022 Q3 | 907 Million CNY | -52.22% |
| 2021 Q3 | 1.33 Billion CNY | 64.1% |
| 2021 Q4 | 1.2 Billion CNY | -10.03% |
| 2021 FY | - CNY | 485.47% |
| 2021 Q1 | 310.9 Million CNY | 24.02% |
| 2021 Q2 | 813.13 Million CNY | 161.54% |
| 2020 Q2 | 110.73 Million CNY | 447.27% |
| 2020 Q3 | -237.53 Million CNY | -314.5% |
| 2020 Q4 | 250.69 Million CNY | 205.54% |
| 2020 FY | - CNY | -43.44% |
| 2020 Q1 | -31.88 Million CNY | -138.67% |
| 2019 FY | - CNY | 6.72% |
| 2019 Q4 | 82.46 Million CNY | -60.65% |
| 2019 Q1 | 151.05 Million CNY | 82.13% |
| 2019 Q2 | 220.65 Million CNY | 46.08% |
| 2019 Q3 | 209.56 Million CNY | -5.03% |
| 2018 Q3 | 221.83 Million CNY | -13.37% |
| 2018 FY | - CNY | 0.33% |
| 2018 Q4 | 82.93 Million CNY | -62.61% |
| 2018 Q2 | 256.06 Million CNY | 213.94% |
| 2018 Q1 | 81.56 Million CNY | -69.86% |
| 2017 Q1 | 184.76 Million CNY | -7.95% |
| 2017 Q2 | 136.66 Million CNY | -26.03% |
| 2017 Q3 | 127.27 Million CNY | -6.88% |
| 2017 Q4 | 270.61 Million CNY | 112.63% |
| 2017 FY | - CNY | 41.26% |
| 2016 Q2 | 138.84 Million CNY | 192.28% |
| 2016 FY | - CNY | 14.21% |
| 2016 Q4 | 200.72 Million CNY | 80.89% |
| 2016 Q1 | 47.5 Million CNY | -81.29% |
| 2016 Q3 | 110.96 Million CNY | -20.08% |
| 2015 Q2 | 132.33 Million CNY | 107.63% |
| 2015 Q4 | 253.92 Million CNY | 427.14% |
| 2015 Q3 | 48.16 Million CNY | -63.6% |
| 2015 Q1 | 63.73 Million CNY | -91.66% |
| 2015 FY | - CNY | -35.39% |
| 2014 FY | - CNY | 225.05% |
| 2014 Q3 | 51.4 Million CNY | -92.45% |
| 2014 Q1 | 51.37 Million CNY | -28.83% |
| 2014 Q4 | 764.03 Million CNY | 1386.41% |
| 2014 Q2 | 680.96 Million CNY | 1225.41% |
| 2013 FY | - CNY | -49.48% |
| 2013 Q2 | 33.7 Million CNY | -40.42% |
| 2013 Q3 | 17.54 Million CNY | -47.95% |
| 2013 Q1 | 56.56 Million CNY | 4.76% |
| 2013 Q4 | 72.19 Million CNY | 311.52% |
| 2012 Q2 | 184.1 Million CNY | -1.98% |
| 2012 Q4 | 53.99 Million CNY | -38.47% |
| 2012 Q1 | 187.83 Million CNY | -3.1% |
| 2012 Q3 | 87.75 Million CNY | -52.33% |
| 2012 FY | - CNY | -13.29% |
| 2011 FY | - CNY | 82.98% |
| 2011 Q3 | 214.4 Million CNY | 0.0% |
| 2011 Q4 | 193.83 Million CNY | -9.6% |
| 2010 FY | - CNY | 205.25% |
| 2009 FY | - CNY | 0.0% |